Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Katherine Peters

Neuro Oncology · Duke University

View

Dr. Soma Sengupta

Neuro Oncology · Tufts

View

Dr. Alissa Thomas

Neuro Oncology · UVM

View

Dr. Akanksha Sharma

Neuro Oncology · Sutter Health

View

Dr. Jonathan Rosand

Neurocritical Care · Broad Institute

View

Dr. Jinsy Andrews

ALS · NYU Langone

View

Dr. Maisha Robinson

Hospice & Palliative Care · Mayo Clinic Florida

View

Dr. Michael Kentris

Epilepsy · St. Elizabeth Medical Center

View

Dr. Daniel Correa

Epilepsy · AECOM

View

Dr. Aaron Berkowitz

General Neurology · UCSF

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas.

    Jun 7, 2024DOI: 10.3174/ajnr.a8219Journal ArticleAJNR

    Written by: Joon Tae KimSe Jung Chris ChangArsalan HaghdelRohan R RamakrishnaSusan C PannulloTheodore H SchwartzJoseph R OsborneRajiv S MaggeHoward A FineBabacar CissePhilip StiegEaton LinMichelle RoytmanJoshua D PalmerNicolas A KarakatsanisDavid PisapiaBenjamin LiechtyJonathan P S KniselyJana Ivanidze

    Find these authors on Roon

    RR

    Dr. Rohan Ramakrishna

    Brain & Spinal Tumor · WCM

    RM

    Dr. Rajiv Magge

    Neuro Oncology · NYP Weill Cornell

    Summary

    BACKGROUND AND PURPOSE: WHO grade 3 meningiomas are rare and poorly understood and have a higher propensity for recurrence, metastasis, and worsened clinical outcomes compared with lower-grade meningiomas. The purpose of our study was to prospectively evaluate the molecular profile, PET characteristics, and outcomes of patients with World Health Organization grade 3 meningiomas who were imaged with gallium 68 (68Ga) DOTATATE PET/MR imaging.MATERIALS AND METHODS: Patients with World Health Organization grade 3 meningiomas enrolled in our prospective observational cohort evaluating the utility of (68Ga) DOTATATE PET/MR imaging in somatostatin receptor positive brain tumors were included. We stratified patients by de novo-versus-secondary-progressive status and evaluated the differences in the PET standard uptake value, molecular profiles, and clinical outcomes.RESULTS: Patients met the inclusion criteria (secondary-progressive: 7/14; de novo: 7/14). The secondary-progressive cohort had a significantly higher per-patient number of surgeries (4.1 versus 1.6; P= .011) and trended toward a higher number of radiation therapy courses (2.4 versus 1.6; P= .23) and cumulative radiation therapy doses (106Gy versus 68.3Gy; P= .31). The secondary-progressive cohort had a significantly lower progression-free survival compared with the de novo cohort (4.8 versus 37.7 months; P= .004). Secondary-progressive tumors had distinct molecular pathology profiles with higher numbers of mutations (3.5 versus 1.2; P= .024). Secondary-progressive tumors demonstrated higher PET standard uptake values (17.1 versus 12.4; P= .0021).CONCLUSIONS: Our study confirms prior work illustrating distinct clinical outcomes in secondary-progressive and de novo World Health Organization grade 3 meningiomas. Furthermore, our findings support (68Ga) DOTATATE PET/MR imaging as a useful management strategy in World Health Organization grade 3 meningiomas and provide insight into meningioma biology, as well as clinical management implications.
    RMDr. Rajiv Magge
    Leading Voice

    Dr. Rajiv Magge

    Neurology · Neuro Oncology
    NewYork–Presbyterian Hospital
    drrajivmagge
    New York, NY